When companies look for external quality or regulatory support, the immediate need is often easy to describe. A quality management system needs to be implemented, technical documentation needs to be completed, an audit is approaching, or a particular regulatory submission requires additional support.
These are important deliverables, but they only describe part of the value that experienced QA/RA support can provide.
In practice, some of the most important questions arise much earlier. Which testing strategy makes sense for the device? Does the planned material create additional biological evaluation requirements? What should be validated? Is the clinical evidence being generated suitable for the intended claims? Does a supplier or manufacturing change have wider regulatory consequences?
Decisions like these affect development time, cost and ultimately the route to market. Quality and regulatory expertise is therefore most useful when it is involved in making those decisions, not only documenting them afterwards.
The documents reflect decisions already made
Medical device development inevitably produces a significant amount of documentation. An ISO 13485 quality management system requires controlled processes and records, while technical documentation brings together areas such as design and development, risk management, verification and validation, clinical evidence and post-market activities.
All of this needs to be prepared properly. However, good documentation cannot always compensate for decisions that were made without considering their regulatory consequences.
If a test programme was poorly planned, writing a better test report will not solve the underlying problem. If a clinical investigation used endpoints that do not support the intended claims, this cannot simply be corrected when the Clinical Evaluation Report is written. Similarly, if a material, supplier or manufacturing process is selected without considering its impact on biocompatibility, validation or regulatory documentation, the consequences may only become apparent much later in the project.
This is why we see quality and regulatory work as part of product development itself. The documentation is important, but the decisions that create the documentation are often more important.
Experience can help avoid unnecessary work
Medical device projects involve many decisions that are difficult to evaluate based on the regulatory text alone.
Testing is a good example. A laboratory may offer a technically suitable test, but that does not necessarily mean the test is the best way to address the regulatory question. Existing evidence may already answer part of the question, the proposed sample may not represent the finished device adequately, or another testing approach may be more appropriate for the intended market.
The same applies to material selection, sterilization, packaging, software development, clinical planning and supplier qualification. Each decision can have implications elsewhere in the technical documentation or quality system.
This is where experience from multiple projects becomes valuable. An internal team understandably develops deep knowledge of its own product and organisation. External specialists bring exposure to different technologies, regulatory pathways, notified bodies, laboratories, manufacturers and previous development challenges.
The purpose is not to apply the same solution from one company to another. It is to recognise where a decision may have consequences that are easy to overlook and to identify those questions early enough that the company still has options.
Access to the right expertise at the right time
Modern medical device development covers a broad range of specialist areas. A project may involve quality management, regulatory strategy, clinical evaluation, biological safety, software, cybersecurity, sterilization, manufacturing validation and FDA requirements at different stages.
It is rarely realistic for one internal Quality Manager or Regulatory Manager to have deep practical experience in all of these areas. For many companies, it would also make little sense to maintain every specialist competence permanently in-house when some questions arise only occasionally.
External support can give the internal team access to a wider pool of expertise when it is needed. A biological evaluation question can be addressed by someone with toxicological expertise. A clinical evidence question can involve the clinical team. A software issue can be reviewed together with specialists who understand both development and regulatory requirements.
This is quite different from outsourcing the entire quality or regulatory function. The internal team remains central to the project and retains the product knowledge, organisational context and decision-making responsibility. The external team adds experience and specialist capability around that core.
Quality management should be part of product development
Quality management works best when it is integrated into development rather than operating as a separate documentation stream.
A material-selection discussion may benefit from considering biological evaluation before the material is fixed. A planned supplier change should be reviewed for regulatory and validation impact before implementation. Intended purpose should be sufficiently clear before clinical evidence is planned. Verification activities should be based on what actually needs to be demonstrated rather than on a generic testing checklist.
This type of involvement can also make regulatory work more proportionate. Compliance does not automatically mean doing more testing, producing more documents or creating more processes.
For example, a biological evaluation may show that existing information can address part of the evidence need without additional testing. A clinical evaluation may identify a very specific evidence gap instead of leading directly to a large clinical investigation. A verification strategy may demonstrate that one well-designed test provides more useful evidence than several loosely connected activities.
The aim is not to reduce regulatory work for its own sake. It is to make sure that the work being performed is relevant to the device and supports the evidence that will ultimately be required.
Choosing the right external partners matters too
Medical device companies also depend heavily on organisations outside their own walls.
Testing laboratories, contract manufacturers, sterilization providers, software developers, clinical sites and other specialist suppliers may all contribute to the finished product. Their technical capability matters, but so does their experience with regulated medical devices and the quality of the documentation they can provide.
The lowest quotation is not necessarily the most cost-effective option if the work later needs to be repeated or supplemented.
Experience from previous projects can help manufacturers understand what to ask potential partners, which documentation will be needed, how responsibilities should be divided and where regulatory risks may arise. It can also help identify laboratories, notified bodies and specialist partners that are suited to the particular device and project rather than simply choosing the largest or most familiar provider.
These decisions can have a significant effect on both project cost and timeline.
Efficiency comes from getting more decisions right the first time
When companies compare external support, it is natural to look at hourly rates and how quickly specific documents can be produced.
Those factors matter, but they do not always determine the overall cost of the regulatory project.
Much larger delays can arise when work needs to be repeated. A verification activity may need to be redone after a design change. Clinical data may not adequately support the intended claim. Material documentation may prove insufficient for biological evaluation. A supplier change may trigger additional validation that was not considered when the decision was made.
Avoiding these situations can save considerably more time than producing an individual document a few days faster.
This is one reason we believe QA/RA expertise should be involved throughout development and market-access planning. The role is not to find shortcuts around regulatory requirements, but to help the company choose a sensible and proportionate way of meeting them.
More than the final deliverable
A QMS, technical file, CER or regulatory submission is a concrete result of QA/RA work, and it needs to be done well.
But the expertise behind those deliverables is equally important.
The value comes from helping determine what should be tested, what evidence is sufficient, which issues should be addressed early, which external partners are appropriate and how development decisions affect the regulatory pathway later.
At MDS, we work alongside internal teams across quality, regulatory, clinical and technical questions throughout the medical device lifecycle. The scope may be a specific documentation task, a specialist question or broader support throughout development and market entry.
In each case, the objective is the same: to help the company make well-informed decisions and build the required quality and regulatory work around them.
If your team is developing a new device, preparing for market entry or working through a difficult quality or regulatory question, MDS can provide the specialist expertise needed for the next stage.
You can contact us at Kristian@mdsdenmark.dk or via Book a Meeting.